Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06522581
PHASE1

Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy

Sponsor: Armed Forces Hospital, Pakistan

View on ClinicalTrials.gov

Summary

Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.

Key Details

Gender

All

Age Range

1 Day - 30 Days

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2024-01-01

Completion Date

2025-01-01

Last Updated

2024-08-14

Healthy Volunteers

No

Interventions

DRUG

Citicoline Sodium

one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth

Locations (1)

MH

Rawalpindi, Pakistan